396 related articles for article (PubMed ID: 27717206)
1. Epigenetic silencing of miR-200c in breast cancer is associated with aggressiveness and is modulated by ZEB1.
Damiano V; Brisotto G; Borgna S; di Gennaro A; Armellin M; Perin T; Guardascione M; Maestro R; Santarosa M
Genes Chromosomes Cancer; 2017 Feb; 56(2):147-158. PubMed ID: 27717206
[TBL] [Abstract][Full Text] [Related]
2. A Long Non-coding RNA Activated by Transforming Growth Factor-β is an Independent Prognostic Marker of Gastric Cancer.
Saito T; Kurashige J; Nambara S; Komatsu H; Hirata H; Ueda M; Sakimura S; Uchi R; Takano Y; Shinden Y; Iguchi T; Eguchi H; Ehata S; Murakami K; Sugimachi K; Mimori K
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S915-22. PubMed ID: 25986864
[TBL] [Abstract][Full Text] [Related]
3. MiR-508-3p inhibits cell invasion and epithelial-mesenchymal transition by targeting ZEB1 in triple-negative breast cancer.
Guo SJ; Zeng HX; Huang P; Wang S; Xie CH; Li SJ
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6379-6385. PubMed ID: 30338806
[TBL] [Abstract][Full Text] [Related]
4. Expression level of microRNA-200c is associated with cell morphology in vitro and histological differentiation through regulation of ZEB1/2 and E-cadherin in gastric carcinoma.
Kurata A; Yamada M; Ohno SI; Inoue S; Hashimoto H; Fujita K; Takanashi M; Kuroda M
Oncol Rep; 2018 Jan; 39(1):91-100. PubMed ID: 29138864
[TBL] [Abstract][Full Text] [Related]
5. The downregulation of miR-200c/141 promotes ZEB1/2 expression and gastric cancer progression.
Zhou X; Wang Y; Shan B; Han J; Zhu H; Lv Y; Fan X; Sang M; Liu XD; Liu W
Med Oncol; 2015 Jan; 32(1):428. PubMed ID: 25502084
[TBL] [Abstract][Full Text] [Related]
6. Role of miR-200c/miR-141 in the regulation of epithelial-mesenchymal transition and migration in head and neck squamous cell carcinoma.
Tamagawa S; Beder LB; Hotomi M; Gunduz M; Yata K; Grenman R; Yamanaka N
Int J Mol Med; 2014 Apr; 33(4):879-86. PubMed ID: 24424572
[TBL] [Abstract][Full Text] [Related]
7. The miR-506-Induced Epithelial-Mesenchymal Transition is Involved in Poor Prognosis for Patients with Gastric Cancer.
Sakimura S; Sugimachi K; Kurashige J; Ueda M; Hirata H; Nambara S; Komatsu H; Saito T; Takano Y; Uchi R; Sakimura E; Shinden Y; Iguchi T; Eguchi H; Oba Y; Hoka S; Mimori K
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1436-43. PubMed ID: 25707493
[TBL] [Abstract][Full Text] [Related]
8. MiR-200c inhibits metastasis of breast tumor via the downregulation of Foxf2.
Zhang T; Wan JG; Liu JB; Deng M
Genet Mol Res; 2017 Aug; 16(3):. PubMed ID: 28829888
[TBL] [Abstract][Full Text] [Related]
9. microRNA-200c modulates the epithelial-to-mesenchymal transition in human renal cell carcinoma metastasis.
Wang X; Chen X; Wang R; Xiao P; Xu Z; Chen L; Hang W; Ruan A; Yang H; Zhang X
Oncol Rep; 2013 Aug; 30(2):643-50. PubMed ID: 23754305
[TBL] [Abstract][Full Text] [Related]
10. microRNA-203 suppresses invasion and epithelial-mesenchymal transition induction via targeting NUAK1 in head and neck cancer.
Obayashi M; Yoshida M; Tsunematsu T; Ogawa I; Sasahira T; Kuniyasu H; Imoto I; Abiko Y; Xu D; Fukunaga S; Tahara H; Kudo Y; Nagao T; Takata T
Oncotarget; 2016 Feb; 7(7):8223-39. PubMed ID: 26882562
[TBL] [Abstract][Full Text] [Related]
11. Magnolol regulates miR-200c-3p to inhibit epithelial-mesenchymal transition and retinoblastoma progression by modulating the ZEB1/E-cadherin axis in vitro and in vivo.
Lai YH; Liu WL; Lee TY; Kuo CW; Liu YR; Huang CY; Chen YH; Chen IL; Wu SH; Wang SC; Lee PY; Liu CC; Lo J; Chang YC; Kuo HF; Hsieh CC; Li CY; Liu PL
Phytomedicine; 2023 Feb; 110():154597. PubMed ID: 36603340
[TBL] [Abstract][Full Text] [Related]
12. Expression of miR-9 and miR-200c, ZEB1, ZEB2 and E-cadherin in Non-Small Cell Lung Cancers in Iran.
Nourmohammadi B; Tafsiri E; Rahimi A; Nourmohammadi Z; Daneshvar Kakhaki A; Cho W; Karimipoor M
Asian Pac J Cancer Prev; 2019 Jun; 20(6):1633-1639. PubMed ID: 31244281
[TBL] [Abstract][Full Text] [Related]
13. The Status of
Muñoz-Hidalgo L; San-Miguel T; Megías J; Serna E; Calabuig-Fariñas S; Monleón D; Gil-Benso R; Cerdá-Nicolás M; López-Ginés C
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396457
[TBL] [Abstract][Full Text] [Related]
14. UTMD inhibit EMT of breast cancer through the ROS/miR-200c/ZEB1 axis.
Shi D; Guo L; Sun X; Shang M; Meng D; Zhou X; Liu X; Zhao Y; Li J
Sci Rep; 2020 Apr; 10(1):6657. PubMed ID: 32313093
[TBL] [Abstract][Full Text] [Related]
15. E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells.
Tryndyak VP; Beland FA; Pogribny IP
Int J Cancer; 2010 Jun; 126(11):2575-83. PubMed ID: 19839049
[TBL] [Abstract][Full Text] [Related]
16. Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells.
Manavalan TT; Teng Y; Litchfield LM; Muluhngwi P; Al-Rayyan N; Klinge CM
PLoS One; 2013; 8(4):e62334. PubMed ID: 23626803
[TBL] [Abstract][Full Text] [Related]
17. Coordinated regulation of β-tubulin isotypes and epithelial-to-mesenchymal transition protein ZEB1 in breast cancer cells.
Lobert S; Graichen ME; Morris K
Biochemistry; 2013 Aug; 52(32):5482-90. PubMed ID: 23869586
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
Gwak JM; Kim HJ; Kim EJ; Chung YR; Yun S; Seo AN; Lee HJ; Park SY
Breast Cancer Res Treat; 2014 Aug; 147(1):39-49. PubMed ID: 25086633
[TBL] [Abstract][Full Text] [Related]
19. MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer.
Bai WD; Ye XM; Zhang MY; Zhu HY; Xi WJ; Huang X; Zhao J; Gu B; Zheng GX; Yang AG; Jia LT
Int J Cancer; 2014 Sep; 135(6):1356-68. PubMed ID: 24615544
[TBL] [Abstract][Full Text] [Related]
20. Involvement of epigenetics and EMT-related miRNA in arsenic-induced neoplastic transformation and their potential clinical use.
Michailidi C; Hayashi M; Datta S; Sen T; Zenner K; Oladeru O; Brait M; Izumchenko E; Baras A; VandenBussche C; Argos M; Bivalacqua TJ; Ahsan H; Hahn NM; Netto GJ; Sidransky D; Hoque MO
Cancer Prev Res (Phila); 2015 Mar; 8(3):208-21. PubMed ID: 25586904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
